文献速递胸部肿瘤

真核翻译起始因子6对非小细胞肺癌发生发展的影响

Influence of eukaryotic translation initiation factor 6 on non-small cell lung cancer development and progression.
PubMed 文献 · Eur J Cancer · 2018-08-01

该研究探讨真核翻译起始因子6(eIF6)在非小细胞肺癌(NSCLC)中的作用。基于组织微阵列和新鲜冰冻肺组织免疫组化数据,发现肺腺癌和鳞癌中eIF6蛋白表达显著高于健康肺组织;eIF6高表达与腺癌患者总生存期缩短相关,但与鳞癌无关。在肺癌细胞系中敲低eIF6可抑制增殖、诱导凋亡,并导致pre-rRNA加工和60S核糖体成熟缺陷。

要点

  • 肺腺癌和鳞癌组织中eIF6蛋白表达显著高于健康肺组织。
  • eIF6高表达与肺腺癌患者总生存期缩短相关,与鳞癌无关。
  • 敲低eIF6抑制肺癌细胞增殖、诱导凋亡并导致核糖体成熟缺陷。

核心结论

  • eIF6在NSCLC中上调,可能参与NSCLC的发生发展,并具有作为新治疗策略靶点的潜力。

研究设计与样本

  • 基于组织微阵列和新鲜冰冻肺组织的免疫组化数据,比较NSCLC与健康肺组织中eIF6蛋白表达。
  • 在肺腺癌和鳞癌细胞系中敲低eIF6,观察细胞增殖、凋亡及核糖体生物合成的影响。
  • 分析eIF6表达水平与肺腺癌和鳞癌患者总生存期的关联。

主要发现

  • 肺腺癌和鳞癌组织中eIF6蛋白表达显著高于健康肺组织。
  • eIF6高表达与肺腺癌患者总生存期缩短相关,但与鳞癌患者总生存期无关。
  • 在肺腺癌和鳞癌细胞系中敲低eIF6可抑制细胞增殖并诱导凋亡。
  • 敲低eIF6导致pre-rRNA加工和核糖体60S亚基成熟缺陷。

临床怎么用

  • eIF6高表达可能作为肺腺癌预后不良的参考指标。
  • eIF6可能成为NSCLC(尤其是腺癌)的潜在治疗靶点,但尚需进一步临床验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related death worldwide. Dysregulation of protein synthesis plays a major role in carcinogenesis, a process regulated at multiple levels, including translation of mRNA into proteins. Ribosome assembly requires correct association of ribosome subunits, which is ensured by eukaryotic translation initiation factors (eIFs). eIFs have become targets in cancer therapy studies, and promising data on eIF6 in various cancer entities have been reported. Therefore, we hypothesised that eIF6 represents a crossroad for pulmonary carcinogenesis. High levels of eIF6 are associated with shorter patient overall survival in adenocarcinoma (ADC), but not in squamous cell carcinoma (SQC) of the lung. We demonstrate significantly higher protein expression of eIF6 in ADC and SQC than in healthy lung tissue based on immunohistochemical data from tissue microarrays (TMAs) and on fresh frozen lung tissue. Depletion of eIF6 in ADC and SQC lung cancer cell lines inhibited cell proliferation and induced apoptosis. Knockdown of eIF6 led to pre-rRNA processing and ribosomal 60S maturation defects. Our data indicate that eIF6 is upregulated in NSCLC, suggesting an important contribution of eIF6 to the development and progression of NSCLC and a potential for new treatment strategies against NSCLC.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Gantenbein N, Bernhart E, Anders I, et al. Influence of eukaryotic translation initiation factor 6 on non-small cell lung cancer development and progression. Eur J Cancer. 2018. PMID: 30077122. doi:10.1016/j.ejca.2018.07.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。